Literature DB >> 16906410

Osteoporosis associated with gyrate atrophy: a case report.

Isik Ahmet1, Koca Suleyman Serdar.   

Abstract

Gyrate atrophy (GA) is a rare degenerative, hereditary disease characterized by markedly high serum ornithine levels resulting from the deficiency of ornithine-delta-amino transferase (OAT), a mitochondrial matrix enzyme. Hyperornithinaemia is accompanied by lysinuria and reduced lysine plasma levels in GA. Type I collagen is known to play a role in osteoporosis pathogenesis. Lysine has a role in cross ligament formation of type I collagen, a bone matrix element, and thus, in bone strength. Although the most common complaint in GA is visual problems, the disease may include muscle involvement, as well. Reduced physical activity resulting from muscle involvement and hypolysinemia in GA may lead to osteoporosis. However, there is no data in the literature concerning the relation between GA and osteoporosis. In this report a GA case with early osteoporosis, besides visual deterioration and muscular signs, is reported, and the relation between GA and osteoporosis is emphasized for the first time.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16906410     DOI: 10.1007/s10633-006-9012-2

Source DB:  PubMed          Journal:  Doc Ophthalmol        ISSN: 0012-4486            Impact factor:   2.379


  18 in total

1.  Hyperornithinemia associated with gyrate atrophy of the choroid and retina in a child with myopia.

Authors:  A Shenoi; N L; R Christopher
Journal:  Indian Pediatr       Date:  2001-08       Impact factor: 1.411

2.  Creatine corrects muscle 31P spectrum in gyrate atrophy with hyperornithinaemia.

Authors:  K Heinänen; K Näntö-Salonen; M Komu; M Erkintalo; A Alanen; O J Heinonen; K Pulkki; E Nikoskelainen; I Sipilä; O Simell
Journal:  Eur J Clin Invest       Date:  1999-12       Impact factor: 4.686

3.  Muscle creatine phosphate in gyrate atrophy of the choroid and retina with hyperornithinaemia--clues to pathogenesis.

Authors:  K Heinänen; K Näntö-Salonen; M Komu; M Erkintalo; O J Heinonen; K Pulkki; M Valtonen; E Nikoskelainen; A Alanen; O Simell
Journal:  Eur J Clin Invest       Date:  1999-05       Impact factor: 4.686

Review 4.  The role of exercise in the prevention and treatment of osteoporosis and osteoarthritis.

Authors:  N A Sharkey; N I Williams; J B Guerin
Journal:  Nurs Clin North Am       Date:  2000-03       Impact factor: 1.208

Review 5.  Collagen cross-links in mineralizing tissues: a review of their chemistry, function, and clinical relevance.

Authors:  L Knott; A J Bailey
Journal:  Bone       Date:  1998-03       Impact factor: 4.398

6.  [Experimental osteoporosis caused by estrogen deficiency in rats. Role of a lactose, L-arginine and L-lysine combination in the prevention and therapy].

Authors:  M Fini; R Giardino; R Mongiorgi; G Cantelli Forti; S Gnudi; N Nicoli Aldini; C Valdrè; D Piotti; G Giavaresi; L Orienti; M Rocca; A Sapone; A Rossetti
Journal:  Minerva Med       Date:  1996-03       Impact factor: 4.806

7.  Human osteopenic bone-derived osteoblasts: essential amino acids treatment effects.

Authors:  Paola Torricelli; Milena Fini; Gianluca Giavaresi; Roberto Giardino
Journal:  Artif Cells Blood Substit Immobil Biotechnol       Date:  2003-02

8.  Vitamin B6-responsive ornithine aminotransferase deficiency with a novel mutation G237D.

Authors:  Yumiko Ohkubo; Akihito Ueta; Tetsuya Ito; Satoshi Sumi; Mari Yamada; Katsuko Ozawa; Hajime Togari
Journal:  Tohoku J Exp Med       Date:  2005-04       Impact factor: 1.848

9.  Gyrate atrophy of the choroid and retina with hyperornithinemia: tubular aggregates and type 2 fiber atrophy in muscle.

Authors:  I Sipilä; O Simell; J Rapola; K Sainio; L Tuuteri
Journal:  Neurology       Date:  1979-07       Impact factor: 9.910

10.  Dietary L-lysine and calcium metabolism in humans.

Authors:  R Civitelli; D T Villareal; D Agnusdei; P Nardi; L V Avioli; C Gennari
Journal:  Nutrition       Date:  1992 Nov-Dec       Impact factor: 4.008

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.